Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

SAB Biotherapeutics (SABS) Income from Continuing Operations: 2020-2024

Historic Income from Continuing Operations for SAB Biotherapeutics (SABS) over the last 5 years, with Dec 2024 value amounting to -$41.9 million.

  • SAB Biotherapeutics' Income from Continuing Operations fell 16.60% to -$12.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$42.6 million, marking a year-over-year increase of 6.57%. This contributed to the annual value of -$41.9 million for FY2024, which is 0.59% up from last year.
  • SAB Biotherapeutics' Income from Continuing Operations amounted to -$41.9 million in FY2024, which was up 0.59% from -$42.2 million recorded in FY2023.
  • SAB Biotherapeutics' Income from Continuing Operations' 5-year high stood at $20.1 million during FY2020, with a 5-year trough of -$42.2 million in FY2023.
  • In the last 3 years, SAB Biotherapeutics' Income from Continuing Operations had a median value of -$41.9 million in 2024 and averaged -$34.3 million.
  • As far as peak fluctuations go, SAB Biotherapeutics' Income from Continuing Operations plummeted by 185.24% in 2021, and later increased by 0.59% in 2024.
  • SAB Biotherapeutics' Income from Continuing Operations (Yearly) stood at $20.1 million in 2020, then slumped by 185.24% to -$17.1 million in 2021, then declined by 9.31% to -$18.7 million in 2022, then slumped by 125.14% to -$42.2 million in 2023, then increased by 0.59% to -$41.9 million in 2024.